Clinical Observation of Kato Pury Combined with Sodium Tanshinone IIa Sulfonate in Treatment of Pulmonary Heart Disease with Heart Failure

Objective: To observe the effect and adverse reaction of Kato Pury combined with sodium tanshinone IIa sulfonate in treatment of pulmonary heart disease with heart failure. Methods: 57 cases of patients with pulmonary heart disease from 2009 May to 2013 May were selected,and randomly divided into observation group of 30 cases,27 cases in the control group. The control group were given conventional anti infection,removing phlegm,arresting cough and relieving asthma,vascular dilation,strengthening heart and diuresis. The observation group didn't use the asodilator drugs on the basis of the treatment of control group,and the strengthening heart and diuresis drug were extenuated to the original 1 /2,and given the Kato Pury oral and intravenous sodium tanshinone IIa sulfonate. To observed the improvement of the clinical symptoms and pulmonary artery systolic pressure in two groups 2 weeks later. Results: Both of the two groups of patients were improved,but there was a significant difference. The patients in observation group efficiency was up to 86. 67%,the effective rate of control group was 66. 67%,there was statistical significance( P 0. 05). Pulmonary artery systolic pressure of two groups decreased,and the observation group affects more obviously( P 0. 05). Conclusion: Kato Pury combined with sodium tanshinone IIa sulfonate is good at treatment of chronic pulmonary heart disease,and the drug price is low,and there is less adverse reactions,which is worthy of clinical application.